Table 2.

Clinical response and outcomes

	A (Placebo; PLAC)	B (Bevacizumab; BEV)	Total
	n = 48	n = 48	n = 96
Best Overall Response	n (%)	n (%)	n (%)
CR	4(8)	6(13)	10(10)
PR	22(46)	23(48)	45(47)
Stable	13(27)	9(19)	22(23)
PD	6(13)	5(10)	8(8)
Not evaluable	3(6)	5(10)	8(8)
Progression-Free Survival
# of events	44	39	83
Median in months(95% CI)	11.1(8.7–12.4)	13.8(10.6–22.5)
HR* (95%CI), p value**
Univariate		0.73(0.43–1.23),0.24
Multivariable***		1.09(0.61–1.97),0.75
Overall Survival
# of events	32	27	59
Median Follow-up (months)	71.4	70.6	70.7
Median in months(95% CI)	49.1(37.2–67.4)	62.9(34.4–72.8 +)
HR* (95%CI), p value**
Univariate		1.09(0.61–1.97),p = 0.75
Multivariable***		1.12(0.62–2.04),p = 0.69

*Bevacizumab vs. placebo

**P-values are two-sided and are based on stratified test using stratification factors at randomization

***Adjusted for Age, ERPR, Primary surgery

 + last censored observation as upper limit not reached